MINIMAL RESIDUAL DISEASE ASSESMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA BY MULTICOLOUR FLOW CYTOMETRY (LITERATURE REVIEW)

MINIMAL RESIDUAL DISEASE ASSESMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA BY MULTICOLOUR FLOW CYTOMETRY (LITERATURE REVIEW)

Patients with acute myeloid leukemia (AML) have a high risk of relapse. Determination of the presence of residual tumor cells during the remission of AML allows predicting the onset of relapse. Slow decrease of blast cells after induction courses is associated with a high probability of relapse. The...

Full description

Saved in:

Bibliographic Details
Main Authors:	T. I. Lobanova, I. V. Galtseva, E. N. Parovichnikova
Format:	Article
Language:	Russian
Published:	ABV-press 2018-05-01
Series:	Онкогематология
Subjects:	minimal residual disease hematology chemotherapy relapse
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/279
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

FLOW CYTOMETRY IN THE DIAGNOSIS AND MONITORING OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA
by: I. V. Galtseva, et al.
Published: (2017-06-01)

CLINICAL ANALYSIS AND OPTIMIZATION OF POST-REMISSION THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH MINIMAL RESIDUAL DISEASE AS DETERMINED BY FLOW CYTOMETRY
by: Daichi Inoue, et al.
Published: (2010-08-01)

STUDY OF MINIMAL RESIDUAL DISEASE BY MULTICOLOR FLOW CYTOMETRY IN MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
by: I. V. Galtseva, et al.
Published: (2017-06-01)

Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis
by: Weiling Xu, et al.
Published: (2024-11-01)

Minimal residual disease and outcomes of allogeneic hematopoietic stem cell transplantation in patients with acute leukemia
by: I. V. Galtseva, et al.
Published: (2024-12-01)

MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
by: Maria Ilaria Del Principe
Published: (2016-10-01)

Modern possibilities for diagnosing and tumor clone monitoring, determined by multicolor flow cytometry, in Waldenstrom’s macroglobulinemia
by: A. B. Loginova, et al.
Published: (2025-05-01)

Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia
by: Fatima Hameed Ahmad, et al.
Published: (2024-09-01)

The emerging role of next-generation sequencing in minimal residual disease assessment in acute lymphoblastic leukemia: a systematic review of current literature
by: Andreea-Iulia Ștefan, et al.
Published: (2025-04-01)

Flow cytometric minimal residual disease monitoring in children with acute lymphoblastic leukemia treated by regimens with reduced intensity
by: A. M. Popov, et al.
Published: (2015-12-01)

Flow cytometry in the diagnosis of plasma cell tumors and assessment of minimal residual disease
by: L. Yu. Grivtsova, et al.
Published: (2021-09-01)

STANDARDIZATION OF FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE MONITORING IN CHILDREN WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. RUSSIA–BELARUS MULTICENTER GROUP EXPERIENCE
by: A. M. Popov, et al.
Published: (2017-01-01)

Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease
by: M. A. Shervashidze, et al.
Published: (2020-10-01)

High-Sensitivity Flow Cytometry for the Reliable Detection of Measurable Residual Disease in Hematological Malignancies in Clinical Laboratories
by: María Beatriz Álvarez Flores, et al.
Published: (2024-12-01)

Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer
by: Oluseyi Abidoye, et al.
Published: (2025-01-01)

Methodological aspects of diagnostics and minimal residual disease monitoring in infant acute leukemias
by: G. A. Tsaur, et al.
Published: (2016-03-01)

Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches
by: OA Beznos, et al.
Published: (2017-04-01)

Ibrutinib in the Treatment of Relapsed Chronic Lymphocytic Leukemia
by: EA Stadnik, et al.
Published: (2018-01-01)

Efficacy and safety of blinatumomab in Chinese patients with relapsed/refractory B-cell acute lymphoblastic leukemia: a single-center retrospective study
by: Yan Wang, et al.
Published: (2025-05-01)

Chronic Lymphocytic Leukemia: Prognostic Significance of Minimal Residual Disease and Potential of Modern Methods of Its Diagnosis and Therapy (Literature Review)
by: AYu Kuvshinov, et al.
Published: (2016-04-01)

CURRENT STRATEGIES FOR THE DETECTION OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
by: Juliana Maria Camargos Rocha, et al.
Published: (2016-04-01)

Combinatory Flowcytometric Approach in Pediatric Acute Lymphoid Leukemia Identifies Surrogate Minimal Residual Disease Markers
by: Noreen Grace George, et al.
Published: (2025-03-01)

FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India
by: Dipesh Dave, et al.

Low Dose Cytarabine and Cladribine for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Clinical Experience
by: SV Gritsaev, et al.
Published: (2016-01-01)

Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy
by: Wen-Jing Yu, et al.
Published: (2024-12-01)

Management of isolated recurrence of extramedullary myeloid tumor at a single site
by: Muddu Vamshi Krishna, et al.
Published: (2013-01-01)

Evaluation of two methods for counting residual leukocytes in leukoreduced packed red cells: Flow cytometry and fully automated cell counter
by: Mamta Shah, et al.
Published: (2024-12-01)

Treatment of Pediatric Acute Lymphoblastic Leukemia in India as per modified BFM 95 protocol with Minimal Residual Disease monitoring
by: Dhwanee Thakkar, et al.
Published: (2025-12-01)

Diagnosis of Acute Lymphoblastic Leukemia Originating From T-Lineage Precursors and Approaches to Minimal Residual Disease Monitoring
by: OA Chernysheva, et al.
Published: (2018-12-01)

Increased Th17 and Treg levels in peripheral blood positively correlate with minimal residual disease in acute myeloid leukaemia
by: Zhimin Wang, et al.
Published: (2024-12-01)

Landscape of Genetic Alterations in Patients with Acute Myeloid Leukemia and the Implications in Personalized Medicine
by: Hwei-Fang Tien
Published: (2025-04-01)

Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries
by: Michelle Morcos-Sandino, et al.
Published: (2025-05-01)

Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia
by: YuV Mirolyubova, et al.
Published: (2018-04-01)

Significance of immunophenotypic, cytogenetic, and molecular markers in adult patients with T-cell lymphoblastic leukemia
by: A. N. Vasileva, et al.
Published: (2024-04-01)

Anesthetic management of minimally invasive intervention in children's oncohematology: preoperative patient management protocol
by: V. V. Shchukin, et al.
Published: (2014-07-01)

The impact of residual symptoms on relapse and quality of life among Thai depressive patients
by: Hiranyatheb T, et al.
Published: (2016-12-01)

Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01)

Estimation of Reverberation Time in Classrooms Using the Residual Minimization Method
by: Artur NOWOSWIAT, et al.
Published: (2017-11-01)

Association of Clinical Features and Hematological Laboratories between Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia
by: Wulyo Rajabto, et al.
Published: (2018-03-01)

Late relapses in those with residual tuberculous changes in the lungs
by: G. K. Guseynov, et al.
Published: (2016-02-01)